과민성 대장 증후군(IBS) 치료 시장 규모, 점유율 및 성장 분석 : 약제 클래스별, 질환 유형별, 치료법별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Irritable Bowel Syndrome Treatment Market size was valued at USD 3.8 Billion in 2024 and is poised to grow from USD 4.11 Billion in 2025 to USD 7.72 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global market for irritable bowel syndrome (IBS) treatment is significantly driven by the increasing incidence of functional gastrointestinal disorders and heightened patient awareness, transforming a previously underdiagnosed condition into a prominent therapeutic opportunity. This market includes a diverse range of treatments such as prescription medications, over-the-counter solutions, microbiome-focused therapies, and behavioral interventions. The shift from symptomatic management to targeted strategies, like low-FODMAP diets and gut-brain axis modulators, underscores the sector's evolution. Key growth factors include innovation in targeted therapies and diagnostics, bolstered by the integration of telemedicine and symptom-tracking apps that enhance adherence and outcomes. Additionally, AI is revolutionizing personalized care by using patient data to create tailored treatment plans, further expanding commercial opportunities within this evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Irritable Bowel Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Irritable Bowel Syndrome Treatment Market Segments Analysis

Global irritable bowel syndrome treatment market is segmented by drug class, disease type, treatment type, route of administration, distribution channel, end-user and region. Based on drug class, the market is segmented into Antispasmodics, Laxatives, Antidiarrheals, Antidepressants and Others. Based on disease type, the market is segmented into IBS with Constipation (IBS-C), IBS with Diarrhea (IBS-D) and Mixed IBS (IBS-M). Based on treatment type, the market is segmented into Pharmacological Treatments, Dietary Supplements & Probiotics and Psychological Therapies. Based on route of administration, the market is segmented into Oral and Injectable. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end-user, the market is segmented into Hospitals, Clinics and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Irritable Bowel Syndrome Treatment Market

The growing emphasis on the gut microbiome has led to a deeper understanding of the pathophysiology of irritable bowel syndrome, paving the way for the identification of innovative therapeutic targets. This evolving scientific landscape encourages both investment and collaboration between academia and the industry, facilitating the transformation of fundamental research into new treatment candidates. Enhanced insights into the underlying mechanisms allow for the creation of therapies that focus on the root causes of the disease rather than merely alleviating symptoms. As a result, this progress enriches the development pipeline and expands the range of treatment options available to cater to the varied needs of patients.

Restraints in the Global Irritable Bowel Syndrome Treatment Market

The global landscape of irritable bowel syndrome treatment faces considerable obstacles due to the high costs linked to the discovery, clinical development, and regulatory approval of new therapies. These financial barriers can deter investment, especially for disorders with diverse symptoms like irritable bowel syndrome. Extended development timelines and the necessity for rigorously controlled clinical trials with established endpoints increase the perceived risks for sponsors, particularly smaller firms, potentially hindering the advancement of new treatments. Additionally, elevated development costs can lead to pricing pressures and difficulties in securing reimbursement, ultimately limiting market penetration and delaying access to innovative therapies for patients.

Market Trends of the Global Irritable Bowel Syndrome Treatment Market

The Global Irritable Bowel Syndrome (IBS) Treatment market is witnessing a significant trend toward personalized therapy, driven by a strong focus on patient stratification and tailored interventions. The emergence of advanced biomarker identification and symptom phenotyping facilitates precise therapeutic matching, enabling more effective and individualized treatment plans. This shift is supported by companion diagnostics and integrated care models that enhance patient outcomes. As manufacturers concentrate on stratified clinical development and robust evidence generation, payers and clinicians increasingly endorse personalized approaches that improve both symptom management and overall patient satisfaction. This trend opens avenues for innovative biologics, small molecules, and combination therapies targeting specific patient segments.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Irritable Bowel Syndrome Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antispasmodics
• Laxatives
• Antidiarrheals
• Antidepressants
• Others

Global Irritable Bowel Syndrome Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• IBS with Constipation (IBS-C)
• IBS with Diarrhea (IBS-D)
• Mixed IBS (IBS-M)

Global Irritable Bowel Syndrome Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Pharmacological Treatments
• Dietary Supplements & Probiotics
• Psychological Therapies

Global Irritable Bowel Syndrome Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Irritable Bowel Syndrome Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Irritable Bowel Syndrome Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Homecare

Global Irritable Bowel Syndrome Treatment Market Size & CAGR (2026-2033)

• North America (Drug Class, Disease Type, Treatment Type, Route of Administration, Distribution Channel, End-User)
  • US
  • Canada
• Europe (Drug Class, Disease Type, Treatment Type, Route of Administration, Distribution Channel, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disease Type, Treatment Type, Route of Administration, Distribution Channel, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disease Type, Treatment Type, Route of Administration, Distribution Channel, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disease Type, Treatment Type, Route of Administration, Distribution Channel, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ironwood Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ardelyx Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sebela Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lexicon Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Salix Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synthetic Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theriva Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (AbbVie)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations